Details for Patent: 8,338,428
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,338,428 protect, and when does it expire?
Patent 8,338,428 protects ABILIFY MAINTENA KIT and is included in one NDA.
This patent has twenty-nine patent family members in twenty-one countries.
Summary for Patent: 8,338,428
Title: | Methods for administering aripiprazole |
Abstract: | The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent. This surprising result suggests that pharmacologically beneficial extended release formulations without the complexities and expense associated with the manufacture microspheres. |
Inventor(s): | Brown; Josiah (Seattle, WA) |
Assignee: | Alkermes, Inc. (Waltham, MA) |
Application Number: | 13/420,822 |
Patent Claim Types: see list of patent claims | Composition; Use; Formulation; |
Drugs Protected by US Patent 8,338,428
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Otsuka Pharm Co Ltd | ABILIFY MAINTENA KIT | aripiprazole | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 202971-001 | Feb 28, 2013 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA | See Plans and Pricing | |||
Otsuka Pharm Co Ltd | ABILIFY MAINTENA KIT | aripiprazole | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 202971-001 | Feb 28, 2013 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | TREATMENT OF SCHIZOPHRENIA | See Plans and Pricing | |||
Otsuka Pharm Co Ltd | ABILIFY MAINTENA KIT | aripiprazole | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 202971-003 | Sep 29, 2014 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | TREATMENT OF SCHIZOPHRENIA | See Plans and Pricing | |||
Otsuka Pharm Co Ltd | ABILIFY MAINTENA KIT | aripiprazole | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 202971-003 | Sep 29, 2014 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA | See Plans and Pricing | |||
Otsuka Pharm Co Ltd | ABILIFY MAINTENA KIT | aripiprazole | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 202971-002 | Feb 28, 2013 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,338,428
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 522200 | See Plans and Pricing | |||
Australia | 2004264886 | See Plans and Pricing | |||
Canada | 2534997 | See Plans and Pricing | |||
China | 102133171 | See Plans and Pricing | |||
China | 1845721 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |